摘要
目的:为探明糠酸莫米松吸入治疗过敏性鼻炎对支气管哮喘的影响。方法:采用自身前后对照试验。将澳大利亚皇家王子爱费尔德(Royal Prince Alfred)医院呼吸内科的25例支气管哮喘合并过敏性鼻炎的患者先单一吸入沙美特罗/丙酸氟替卡松干粉剂50μg/250μg(英文名:Seretide)治疗,每次1吸,每天2次,3月后,然后加用糠酸莫米松鼻腔喷雾剂50μg(商品名:内舒纳)(英文名:Nasonex)治疗,每次每侧鼻腔1喷,每日2次,分别于治疗前、治疗3月后以及加用糠酸莫米松治疗3月后观察用力肺活量(FVC)、第一秒呼气容积(FEV1)、日间哮喘评分及夜间憋醒次数的变化,比较不同治疗方法的疗效。结果:加用糠酸莫米松治疗过敏性鼻炎后,患者的FVC、FEV1、短效β2受体激动剂应用次数、日间哮喘评分及夜间憋醒次数有明显改善,差异有统计学意义(P<0.05)。结论:应用糠酸莫米松治疗过敏性鼻炎,可显著提高支气管哮喘患者的治疗效果。
Objective：To identify the impact on asthma by the treatment of mometasone furoate monohydrate nasal spray to allergic rhinitis.Methods：This was an opened own control study.25 patients with asthma and rhinitis were given inhaled-powder salmeterol/fluticasone50 μg/250 μg（Seretide）,one inhalation each time,twice daily via Diskhaler for 3 months.then added the use of mometasone furoate monohydrate nasal spray（Nasonex） 50 μg,one spray each nasal side each time,twice daily.To determine the efficacy of different treatment methods.The forced expiratory volume in one second（FEV1）,the forced vital capacity（FVC）,asthma symptom scores,nocturnal-awakening times and the amount of use of inhaled short-actingβ2-adrenoceptor agonist bronchodilators were observed respectively before the treatment,after the treatment of salmeterol/fluticasone 50 μg/250 μg for 3 months,and after the treatment of inhaled-powder salmeterol/fluticasone combined with Nasonex for 3 months.Results：The treatment of inhaled-powder salmeterol/fluticasone combined with mometasone furoate monohydrate nasal spray improved FEV1,FVC and clinical asthma symptoms,and decreased the amount of the use of inhaled short-actingβ2-adrenoceptor agonist bronchodilators,there were significant differences（P0.05）.Conclusion：The treatment to allergic rhinitis by mometasone furoate monohydrate nasal spray improved the efficacy of the treatment to asthma.
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2010年第3期467-469,共3页
Journal of Chongqing Medical University
